Fulcrum therapeutics announces second quarter 2022 financial results and business update

Cambridge, mass., aug. 11, 2022 (globe newswire) -- fulcrum therapeutics, inc. ® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the second quarter of 2022 and announced a strategic plan to realign internal resources to support the two clinical programs that are expected to be the key drivers of near-term value and extend cash runway.
FULC Ratings Summary
FULC Quant Ranking